⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Senomorphics
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-13 — Interfering in the USP25-SIRT1 Interaction Reduces the Onset of Cellular Senescence: [mechanism-plausible] News report describes USP25–SIRT1 interaction disruption as a senostatic approach to slowing senescence entry, distinct from suppressing established cells’ SASP or killing them; biology suggests reduced entry could let endogenous immune clearance lower cell burden, but the supplied report provides no outcome study confirming that proposed clearance-mediated benefit. [mechanism-plausible] (novelty: 3)
- 2026-10-29 — Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.: [mechanism-plausible] Review proposes lipid-prodrug delivery of senomorphics to modulate senescent adipocytes rather than kill them; biology suggests a route to localized senescence modulation, but the review supplies no new primary outcome data confirming delivery advantages or metabolic benefit. [mechanism-plausible] (novelty: 3)
- 2026-10-07 — Nanoparticle-based senolytic and senomorphic therapies for healthy aging: design principles, translational evidence, and challenges.: Same nanoparticle senotherapy review covers senomorphic delivery alongside senolytics, framing stimulus-responsive carriers as a route to sustained, localized SASP suppression but noting the open question of advantage over oral/systemic small-molecule regimens — synthesis, no primary data. [expert-opinion] (novelty: 3)
- 2026-10-08 — Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.: Same MASLD Perspective positions senomorphic SASP modulation plus metabolic maintenance as the long-term phase following an early senolytic pulse, with biomarker-defined stage stratification determining when SASP suppression (rather than clearance) is appropriate — hypothesis-generating, no new primary data. [expert-opinion] (novelty: 3)
- 2026-09-30 — Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization: cross-connection with parthenolide: Parthenolide’s Ero1L/MAM-stabilization mechanism positions it as a candidate senomorphic — suppressing senescence phenotype rather than clearing cells — in a fibrotic disease context. (novelty: 3)
- 2026-10-06 — Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan: Phenotypic screen of novel flavonoid senotherapeutics (SR29384, SR31133) reported reduced tissue senescence and multi-marker healthspan gains in aging mice — compounds frame primarily as senolytics but the SASP/healthspan readouts overlap senomorphic endpoints; preclinical only. [animal-model] (novelty: 3)
- 2026-10-01 — Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.: Same endothelial TLR4 review nominates spatiotemporally targeted TLR4 inhibition as a senomorphic-adjacent strategy to blunt SASP-driving TLR4 signaling in vascular endothelium without systemic immunosuppression — conceptual framing, no primary outcome data. [mechanism-plausible] (novelty: 3)
- 2026-10-05 — Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells.: cross-connection with cma-activators: CMA decline is reported to rewire the SASP, linking CMA activators to SASP-modulating (senomorphic) strategies. (novelty: 4)
- 2026-10-05 — Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.: Same PRISMA systematic review of human clinical trials covers senomorphics alongside senolytics, finding only preliminary biological/functional readouts and no established clinical efficacy or long-term safety — expert synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-05 — Senotherapeutic potential against xeroderma pigmentosum.: XP patient-derived melanocyte screen: JAK inhibitors and curcuminoids suppressed UV-induced SASP without killing senescent cells, nominating senomorphic strategies for xeroderma pigmentosum photoaging — in vitro only, no outcome data. [mechanism-plausible] (novelty: 3)
- 2026-05-22 — circRNA-engineered macrophages mediate localized MMP9 neutralization to rejuvenate aged bone.: Macrophage-biofactory circRNA-LNPs neutralizing MMP9 reduced skeletal stem-cell senescence and SASP in aged mice, extending the senomorphic concept from small molecules to in vivo-generated biologics acting on a SASP protease — preclinical, no human data. [animal-model] (novelty: 4)
- 2026-06-27 — IL-11 neutralizing antibodies alleviate pulmonary fibrosis in aging mice by inhibiting TGF-β/NOX4/IL-11 signaling pathway.: cross-connection with il-11-neutralizing-antibodies: By neutralizing a SASP-adjacent cytokine (IL-11) and reversing senescent fibroblast profibrotic output without killing the cells, anti-IL-11 behaves as a senomorphic in the aged lung. (novelty: 3)
- 2026-07-12 — Targeting the JAK-STAT signaling pathway ameliorates chemotherapy-induced skin aging.: Mouse and human dermal fibroblast study showing chemotherapy-induced DNA damage activates JAK-STAT to drive fibroblast senescence and SASP in skin, with ruxolitinib acting as a senomorphic that reduces chemo-induced skin aging phenotypes while also suppressing tumor progression — preclinical, no human skin-aging outcome data. [animal-model] (novelty: 3)
- 2026-07-14 — A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.: Same circulating-senescence-biomarker compendium includes senomorphic (SASP-suppressing) interventions among the therapeutic modulators of GDF15/Activin A and related SASP factors, offering a shared noninvasive readout framework for senomorphic trials — review-level synthesis, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-08-01 — Senescent cardiac cells promote thrombus formation and impair fibrinolysis.: Doxorubicin-induced senescent human cardiac fibroblasts and endothelial cells drove thrombin generation and impaired fibrinolysis in vitro; rapamycin as a senostatic reversed the pro-thrombotic phenotype — adds a cardiovascular-coagulation readout to the senomorphic effect catalog, cell-culture only. [mechanism-plausible] (novelty: 3)
- 2026-10-01 — Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.: Syringin added to the senomorphic candidate list via a fibroblast + bleomycin-mouse IPF study showing attenuation of senescence and fibrotic signatures through ATR/CHK1-p53 modulation — preclinical compound-level evidence, no human data. [animal-model] (novelty: 3)
- 2026-05-26 — A taxifolin-zinc nanozyme with SOD-like activity attenuates oxidative-stress-induced senescence and extends lifespan in C. elegans.: cross-connection with taxifolin-zinc-nanozyme: Attenuation of oxidative-stress-induced senescence places this formulation in the senomorphic (senescence-suppressing) rather than senolytic category. (novelty: 3)
- 2026-06-23 — Hydrogel-based senomorphic approaches to modulate cellular senescence and promote tissue rejuvenation.: Review frames hydrogels as dual-function platforms combining material-intrinsic bioactivity with localized, sustained senomorphic cargo delivery to attenuate SASP and support tissue rejuvenation in low-regenerative tissues while sparing resident cells — delivery-paradigm synthesis, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-05-30 — Cell senescence in chronic pain: An integrative perspective on cellular and neural mechanisms.: Same review positions SASP modulators as an alternative to senolytic clearance for chronic pain, arguing that dampening sustained SASP signaling in pain-processing cells could interrupt neuroinflammatory maintenance of pain — mechanistic reframing, no primary outcome data. [mechanism-plausible] (novelty: 3)
- 2026-07-17 — Discovery of a quinoline-based senomorphic agent for the treatment of chronic kidney disease.: Optimized quinoline derivative C36 extended C. elegans lifespan and reduced SASP, senescence markers, and renal fibrosis while improving kidney function in mouse models of senescence and CKD — preclinical compound-level progress, no human data. [animal-model] (novelty: 3)
- 2026-07-29 — Complosome as a key modulator of cellular senescence, aging and age-related diseases.: Review argues intracellular complement (intC3/intC5) drives NF-κB-linked inflammaging and SASP output, nominating complosome inhibition as a senomorphic-adjacent lever to suppress SASP without killing senescent cells; conceptual framing, no primary human or animal outcome data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Interfering in the USP25-SIRT1 Interaction Reduces the Onset of Cellular Senescence
13-nov-2026
novelty 3
per-area 3
strengthens
Sanmiao San Attenuates D-galactose-induced Chondrocyte Senescence by Regulating the FoxM1-p21 Signaling Pathway.
12-nov-2026
novelty 2
per-area 2
strengthens
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
10-nov-2026
novelty 2
per-area 2
strengthens
The neuro-inflammaging triangle: a self-amplifying circuit of protein pathology, senescence-associated secretory phenotype and innate immunity in neurodegenerative disease.
10-nov-2026
novelty 3
per-area 2
mentions
Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment.
29-oct-2026
novelty 3
per-area 3
strengthens
Biomarker-Guided, Stage-Specific Senotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.
08-oct-2026
novelty 3
per-area 3
strengthens
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 2
mentions
Nanoparticle-based senolytic and senomorphic therapies for healthy aging: design principles, translational evidence, and challenges.
07-oct-2026
novelty 3
per-area 3
strengthens
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics
06-oct-2026
novelty 2
per-area 2
mentions
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
06-oct-2026
novelty 3
per-area 3
strengthens
Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.
05-oct-2026
novelty 3
per-area 3
strengthens
Senotherapeutic potential against xeroderma pigmentosum.
05-oct-2026
novelty 3
per-area 3
strengthens
Cellular senescence: six decades of discovery and reinvention.
02-oct-2026
novelty 2
per-area 2
mentions
Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.
01-oct-2026
novelty 3
per-area 3
strengthens
Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.
01-oct-2026
novelty 3
per-area 3
strengthens
Wound Healing, Senescence, and Senotherapeutics.
30-sep-2026
novelty 2
per-area 2
strengthens
Berberine as a multi-hallmark modulator of aging: From AMPK and mitophagy to inflammaging and the SASP.
28-sep-2026
novelty 2
per-area 2
strengthens
Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies.
27-sep-2026
novelty 2
per-area 2
strengthens
Senescence-associated extracellular vesicles in skin aging and regeneration: from pathophysiology to therapeutic opportunities.
22-sep-2026
novelty 2
per-area 2
strengthens
Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.
22-sep-2026
novelty 2
per-area 2
strengthens
Schisandra chinensis Modulates Cellular Senescence through Integrated Regulation of Redox, Mitochondrial, and Inflammatory Homeostasis.
19-sep-2026
novelty 2
per-area 2
strengthens
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
strengthens
Cellular Senescence and SASP in Bladder Ageing: Mechanisms and Emerging Interventions.
17-sep-2026
novelty 2
per-area 2
strengthens
Multidimensional Regulatory Network of Cellular Senescence: From Mechanisms to Theranostics.
15-sep-2026
novelty 2
per-area 2
mentions
The vicious cycle of SASP and inflammaging promotes aging and age-related diseases.
10-sep-2026
novelty 2
per-area 2
mentions
Senescent cardiac cells promote thrombus formation and impair fibrinolysis.
01-aug-2026
novelty 3
per-area 3
strengthens
Complosome as a key modulator of cellular senescence, aging and age-related diseases.
29-jul-2026
novelty 3
per-area 3
strengthens
Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing.
24-jul-2026
novelty 2
per-area 3
strengthens
Natural products targeting cytokine-regulated SASP inflammation networks in Ovarian cancer: Implications on immune escape and molecular resistance.
21-jul-2026
novelty 2
per-area 2
strengthens
Cleaning, Chasing and Calming: Promising Paradigms of Senotherapy in Aging-Related Diseases.
20-jul-2026
novelty 2
per-area 2
introduces
Discovery of a quinoline-based senomorphic agent for the treatment of chronic kidney disease.
17-jul-2026
novelty 3
per-area 3
strengthens
A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.
14-jul-2026
novelty 3
per-area 3
strengthens
Targeting the JAK-STAT signaling pathway ameliorates chemotherapy-induced skin aging.
12-jul-2026
novelty 3
per-area 3
strengthens
The role of cellular senescence in metabolic dysfunction-associated steatotic liver disease.
09-jul-2026
novelty 2
per-area 2
strengthens
Targeting cellular senescence in dermatology: senolytic and senomorphic strategies.
08-jul-2026
novelty 2
per-area 2
introduces
Cellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers.
05-jul-2026
novelty 2
per-area 2
strengthens
From lifespan extension to hallmark-informed gerotherapeutic prioritization: A bibliometric-guided, strategy-oriented review of anti-aging drug research.
28-jun-2026
novelty 3
per-area 2
strengthens
Advances in skin aging: integrating epigenetic, cellular, and immune mechanisms for targeted therapy.
24-jun-2026
novelty 2
per-area 2
mentions
Hydrogel-based senomorphic approaches to modulate cellular senescence and promote tissue rejuvenation.
23-jun-2026
novelty 3
per-area 3
strengthens
Immunosenescence in systemic and multi-organ aging: mechanisms, inter-organ crosstalk, and translational opportunities.
19-jun-2026
novelty 2
per-area 2
mentions
Cellular senescence in Crohn's disease: a double-edged sword in intestinal fibrosis.
12-jun-2026
novelty 2
per-area 2
mentions
Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine.
11-jun-2026
novelty 2
per-area 3
strengthens
Cell senescence in chronic pain: An integrative perspective on cellular and neural mechanisms.
30-may-2026
novelty 3
per-area 3
strengthens
circRNA-engineered macrophages mediate localized MMP9 neutralization to rejuvenate aged bone.
22-may-2026
novelty 4
per-area 4
strengthens
Epigenetic dynamics of cellular senescence: From mechanistic insights to precision senotherapy.
17-mar-2026
novelty 2
per-area 2
strengthens